275
Participants
Start Date
October 31, 2012
Primary Completion Date
April 30, 2013
Study Completion Date
April 30, 2013
Placebo
EP-101 Placebo AM + EP-101 Placebo PM
EP-101 12.5 mcg
EP-101 12.5 mcg AM + EP-101 12.5 mcg PM
EP-101 25 mcg
EP-101 25 mcg AM + EP-101 25 mcg PM
EP-101 50 mcg
EP-101 50 mcg AM + EP-101 50 mcg PM
EP-101 100 mcg
EP-101 100 mcg AM + EP-101 100 mcg PM
Pulmonary Associates of Richmond, Inc., Richmond
North Carolina Clinical Research, Raleigh
American Health Research, Charlotte
South Carolina Pharmaceutical Research, Spartanburg
CU Pharmacuetical Research, Union
Greenville Pharmaceutical Research, Inc, Greenville
Upstate Pharmaceutical Research, Greenville
Gwinnett Biomedical Research, Lawrenceville
Georgia Clinical Research, Austell
Clinical Research of West Florida, Tampa
Clinical Research of West Florida, Clearwater
Jasper Summit Research, LLC, Jasper
New Horizons Clinical Research, Cincinnati
Minnesota Lung Center, Minneapolis
Veritas Clinical Specialities, LTD, Topeka
Baylor College of Medicine, Houston
Central Texas Health Research, New Braunfels
Pulmonary Associates, PA, Phoenix
UCLA David Geffen School of Medicine, Los Angeles
Institute of HealthCare Assessment, Inc., San Diego
Integrated Research Group, Riverside
California Research Medical Group, Inc., Fullerton
Capital Allergy & Respiratory Disease Center, Sacramento
Allergy Associates Research Center, Portland
Clinical Research Institute of Southern Oregon, PC, Medford
Sunstone Medical Research LLC, Medford
Sunovion Respiratory Development Inc.
INDUSTRY